Roche lands Tecentriq trial win, still trails Merck in lung cancer
Monday, October 22, 2018 - 03:00
in Health & Medicine
Roche's Tecentriq plus chemotherapy boosted lung cancer patients' survival by nearly five months, study data released on Monday showed, underscoring benefits of the Swiss group's immunotherapy but still leaving it trailing a rival's drug.